Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 211,91 pts
-0.06%


Last updated : 18/11/2026 - 12h18
🏠 Home   ➤    Stock news

Advicenne: Paris Commercial Court extends safeguard period by six months, until May 2027

The Paris Commercial Court has granted Advicenne six additional months under its safeguard proceedings. The observation period now runs until May 5, 2027, the laboratory said in a press release published on November 17, 2026.


Advicenne: Paris Commercial Court extends safeguard period by six months, until May 2027

A hearing on November 9 and a deadline pushed back to May 2027

The decision was handed down at the hearing held on November 9, 2026 before the Paris Commercial Court. In a press release dated November 3, 2026, the company had presented this hearing as the one marking the end of the observation period of its safeguard proceedings.

At the close of this hearing, the court did not end this phase: it extended it. The company, listed on Euronext Growth Paris, therefore remains under safeguard proceedings until the new deadline.

Sibnayal, flagship product of a laboratory under court protection

Advicenne stated that it will continue to regularly communicate on the various developments in the proceedings. Founded in 2007 and based in Paris, the laboratory develops treatments in nephrology.

Its main product, Sibnayal (ADV7103), holds a marketing authorization for distal renal tubular acidosis in the European Union, the United Kingdom, Saudi Arabia and the United Arab Emirates. It is marketed in more than twenty-five countries in Europe.

Listed in Paris since 2017, Advicenne shares were transferred to Euronext Growth Paris on March 30, 2022.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 2,9 millions d'euros
  • Quarterly revenue: 2,9 millions d'euros
  • Revenue growth: 3,5 %
  • Net income: 4,6 millions d'euros
  • 25,5 millions d'euros
Risks mentioned
  • L'impact de l'accès facilité aux traitements est incertain.
  • Les résultats peuvent différer des projections à cause des risques de marché.
Opportunities identified
  • Les ventes de Sibnayal® continuent de progresser avec des croissances significatives.
  • Le remboursement de Likozam® contribue à une forte croissance des ventes.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours